Evidence map›Paper›PMID 29862271›Full record

ArticleBioMed research international2018

Beneficial Effects of Concentrated Growth Factors and Resveratrol on Human Osteoblasts

Elisa Borsani, Veronica Bonazza, Barbara Buffoli, Pier Francesco Nocini, Massimo Albanese, Francesca Zotti, Francesco Inchingolo, Rita Rezzani, Luigi F Rodella

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 5 pooled it
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 5 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Elisa BorsaniDepartment of Clinical and Experimental Sciences, Division of Anatomy and Physiopathology, University of Brescia, Brescia, Italy.ORCID 0000-0002-9746-0876
Veronica BonazzaDepartment of Clinical and Experimental Sciences, Division of Anatomy and Physiopathology, University of Brescia, Brescia, Italy.
Barbara BuffoliDepartment of Clinical and Experimental Sciences, Division of Anatomy and Physiopathology, University of Brescia, Brescia, Italy.ORCID 0000-0002-8531-7730
Pier Francesco NociniDepartment of Surgery, Dentistry, Pediatric and Gynecology, Division of Oral and Maxillofacial Surgery, University of Verona, Verona, Italy.
Massimo AlbaneseDepartment of Surgery, Dentistry, Pediatric and Gynecology, Division of Oral and Maxillofacial Surgery, University of Verona, Verona, Italy.
Francesca ZottiDepartment of Surgery, Dentistry, Pediatric and Gynecology, Division of Oral and Maxillofacial Surgery, University of Verona, Verona, Italy.
Francesco InchingoloDepartment of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy.
Rita RezzaniDepartment of Clinical and Experimental Sciences, Division of Anatomy and Physiopathology, University of Brescia, Brescia, Italy.ORCID 0000-0002-7515-5846
Luigi F RodellaDepartment of Clinical and Experimental Sciences, Division of Anatomy and Physiopathology, University of Brescia, Brescia, Italy.ORCID 0000-0002-9497-4708
University of Brescia · ITUniversity of Verona · ITUniversity of Bari Aldo Moro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bisphosphonates are primary pharmacological agents against osteoclast-mediated bone loss and widely used in the clinical practice for prevention and treatment of a variety of skeletal conditions, such as low bone density and osteogenesis imperfecta, and pathologies, such as osteoporosis, malignancies metastatic to bone, Paget disease of bone, multiple myeloma, and hypercalcemia of malignancy. However, long-term bisphosphonate treatment is associated with pathologic conditions including osteonecrosis of the jaw, named BRONJ, which impaired bone regeneration process. Clinical management of BRONJ is controversy and one recent approach is the use of platelet concentrates, such as Concentrated Growth Factors, alone or together with biomaterials or antioxidants molecules, such as resveratrol. The aim of the present study was to investigate the

Indexed as

Antigens, DifferentiationCell Culture TechniquesCell DifferentiationCell ProliferationCells, CulturedHumansIntercellular Signaling Peptides and ProteinsOsteoblastsResveratrolStilbenesAntigens, DifferentiationIntercellular Signaling Peptides and ProteinsResveratrolStilbenes

Identifiers

PMID29862271
PMCPMC5976957
OpenAlexW2804364172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.